283 related articles for article (PubMed ID: 32735150)
1. Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.
Ahangari N; Doosti M; Ghayour Mobarhan M; Sahebkar A; Ferns GA; Pasdar A
Ann Med; 2020 Dec; 52(8):462-470. PubMed ID: 32735150
[TBL] [Abstract][Full Text] [Related]
2. The frequency of major
Alrajeh K; AlAzzeh O; Roman Y
Pharmacogenomics; 2023 May; 24(7):381-398. PubMed ID: 37222158
[TBL] [Abstract][Full Text] [Related]
3. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.
Peyser B; Perry EP; Singh K; Gill RD; Mehan MR; Haga SB; Musty MD; Milazzo NA; Savard D; Li YJ; Trujilio G; Voora D
Circ Genom Precis Med; 2018 Sep; 11(9):e002228. PubMed ID: 30354330
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
Cooper-DeHoff RM; Niemi M; Ramsey LB; Luzum JA; Tarkiainen EK; Straka RJ; Gong L; Tuteja S; Wilke RA; Wadelius M; Larson EA; Roden DM; Klein TE; Yee SW; Krauss RM; Turner RM; Palaniappan L; Gaedigk A; Giacomini KM; Caudle KE; Voora D
Clin Pharmacol Ther; 2022 May; 111(5):1007-1021. PubMed ID: 35152405
[TBL] [Abstract][Full Text] [Related]
5. Children Are Not Small Adults: Specific Findings in Statin Exposure and Response in a Growing Population.
Wagner JB
Clin Pharmacol Ther; 2019 Aug; 106(2):278-280. PubMed ID: 30970165
[No Abstract] [Full Text] [Related]
6. The role of
Brunette CA; Vassy JL
Pharmacogenomics; 2021 Jul; 22(11):649-656. PubMed ID: 34196599
[No Abstract] [Full Text] [Related]
7. Pharmacogenomics of cholesterol-lowering therapy.
Schmitz G; Langmann T
Vascul Pharmacol; 2006 Feb; 44(2):75-89. PubMed ID: 16337220
[TBL] [Abstract][Full Text] [Related]
8. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
9. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.
Zhang D; Ding Y; Wang X; Xin W; Du W; Chen W; Zhang X; Li P
Eur J Clin Pharmacol; 2020 Jul; 76(7):939-946. PubMed ID: 32361904
[TBL] [Abstract][Full Text] [Related]
10. Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.
Ahern TP; Damkier P; Feddersen S; Kjærsgaard A; Lash TL; Hamilton-Dutoit S; Lythjohan CB; Ejlertsen B; Christiansen PM; Cronin-Fenton DP
Acta Oncol; 2020 Sep; 59(9):1009-1015. PubMed ID: 32351149
[No Abstract] [Full Text] [Related]
11. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
[TBL] [Abstract][Full Text] [Related]
12. Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins.
Chien KL; Wang KC; Chen YC; Chao CL; Hsu HC; Chen MF; Chen WJ
Pharmacogenomics; 2010 Mar; 11(3):309-17. PubMed ID: 20235787
[TBL] [Abstract][Full Text] [Related]
13. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
Ramakumari N; Indumathi B; Katkam SK; Kutala VK
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
[TBL] [Abstract][Full Text] [Related]
14. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2.
Ferrari M; Guasti L; Maresca A; Mirabile M; Contini S; Grandi AM; Marino F; Cosentino M
Eur J Clin Pharmacol; 2014 May; 70(5):539-47. PubMed ID: 24595600
[TBL] [Abstract][Full Text] [Related]
15. Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia: Pharmacogenetics of Statins.
Ruaño G; Seip R; Windemuth A; Wu AH; Thompson PD
Clin Lab Med; 2016 Sep; 36(3):473-91. PubMed ID: 27514463
[TBL] [Abstract][Full Text] [Related]
16. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI.
Peters BJ; Pett H; Klungel OH; Stricker BH; Psaty BM; Glazer NL; Wiggins KL; Bis JC; de Boer A; Maitland-van der Zee AH
Atherosclerosis; 2011 Aug; 217(2):458-64. PubMed ID: 21741043
[TBL] [Abstract][Full Text] [Related]
17. Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia.
Sorich MJ; Wiese MD; O'Shea RL; Pekarsky B
Pharmacoeconomics; 2013 May; 31(5):377-91. PubMed ID: 23568333
[TBL] [Abstract][Full Text] [Related]
18. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
Canestaro WJ; Austin MA; Thummel KE
Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
[TBL] [Abstract][Full Text] [Related]
19. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of SLCO1B1 single nucleotide variations and their association with hypercholesterolaemia in hypercholesterolemic patients in Gauteng, South Africa.
de Beer R; Outhoff K; Phulukdaree A; Soma P
Xenobiotica; 2021 Aug; 51(8):949-959. PubMed ID: 34154510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
